


**Product Name** : AZD0364  
**Cat. No.** : PC-63271  
**CAS No.** : 2097416-76-5  
**Molecular Formula** : C<sub>24</sub>H<sub>24</sub>F<sub>2</sub>N<sub>8</sub>O<sub>2</sub>  
**Molecular Weight** : 494.507  
**Target** : ERK  
**Solubility** : 10 mM in DMSO



1. Flemington V, et al. *Mol Cancer Ther.* 2021 Feb;20(2):238-249.
2. Ward RA, et al. *J Med Chem.* 2019 Dec 26;62(24):11004-11018.

## Biological Activity

Tizaterkib (AZD0364) is a potent, selective, ATP competitive, orally active **ERK1/2** inhibitor with IC<sub>50</sub> of 0.66 nM in ERK2 biochemical assay, binds similarly to ERK1 and ERK2 with K<sub>i</sub> of 3.9 and 3.8 nM.

AZD0364 inhibits p90RSK phosphorylation with an IC<sub>50</sub> of 5.74 nM in an A375 melanoma cell line containing a BRAFV600E mutation.

AZD0364 potently inhibits ERK1/2 phosphorylation with IC<sub>50</sub> of 1.73 nM, which is more potent than the reported ERK1/2 competitors, SCH772984, GDC-0994, and BVD-523 (ulixertinib).

AZD0364 is highly selective for ERK1/2 in a broader panel of 353 human kinases, with activity against only nine other kinases in this panel: MEK1, COT, BRAF, MEK2, c-RAF, ERK7, CDK2, CDK5, and ARK5.

AZD0364 directly modulates RAS/MAPK pathway signaling, demonstrates in vivo antitumor activity in KRAS- and BRAF-mutant cancer cell line xenograft models.

## References

